patient
diagnosi
ventilatorassoci
pneumonia
vap
aggress
support
manag
pneumonia
aris
hospit
set
remain
challeng
endur
clinic
entiti
hospitalacquir
pneumonia
defin
pneumonia
patient
hospit
day
appear
pneumonia
admiss
earlier
design
healthcar
associ
pneumonia
remov
infecti
diseas
societi
america
idsa
american
thorac
societi
at
patient
recent
contact
healthcar
set
increas
risk
infect
multidrug
resist
mdr
organ
popul
patient
antimicrobi
therapi
determin
clinic
context
ventilatorassoci
pneumoniai
defin
new
pneumonia
patient
intub
least
day
featur
vap
includ
worsen
radiograph
opac
increas
secret
bronchospasm
hemoptysi
worsen
ga
exchang
ventil
earli
treatment
essenti
rapid
deescal
antibiot
face
neg
cultur
result
also
import
sampl
respiratori
tract
necessari
guid
manag
sampl
may
obtain
either
tracheobronchi
aspir
bronchoalveolar
lavag
bal
minib
protect
specimen
brush
psb
care
observ
individu
hospit
bacteri
antibiogram
essenti
provid
treatment
target
resist
profil
institut
common
mdr
pathogen
includ
p
aeruginosa
escheriochia
coli
klebsiella
pneumonia
acinetobact
speci
well
methicillinresist
aureu
high
suspicion
vap
follow
rapid
diagnosi
treatment
critic
import
zilberberg
colleagu
found
thatamong
nearli
patient
aliv
h
hospitalacquir
pneumonia
inappropri
empir
antibiot
therapi
associ
signific
increas
mortal
vs
p
ci
multivari
logist
regress
treatment
escal
chang
risk
death
singlecent
studi
unfortun
treatment
often
delay
one
studi
among
patient
patient
therapi
vap
inappropri
delay
defin
h
pass
vap
onset
provid
appropri
antimicrobi
treatment
delay
write
antibiot
order
primari
reason
delay
therapi
case
endotrach
aspir
prefer
mean
sampl
prior
time
antibiot
initi
multipl
studi
demonstr
techniqu
equival
bronchoscopi
regard
patient
outcom
antibiot
exposur
patient
vap
univers
initi
therapi
mrsa
exampl
vancomycin
linezolid
resist
gramneg
bacteria
pseudomona
aeruginosa
klebsiella
pneumonias
acinetobact
speci
treatment
option
gram
neg
organ
includ
antipseudomon
cephalosporin
cefepim
ceftazidim
antipseudomon
carbapenem
imipenem
meropenem
inhibitor
piperacillintazobactam
combin
therapi
gramneg
bacteria
consid
see
evid
contour
addit
antipseudomon
fluoroquinolon
aminoglycosid
consid
domin
pathogen
one
local
icu
also
contribut
decis
make
appropri
choic
therapi
guid
overal
principl
atsidsa
guidelin
demonstr
impact
hap
collabor
addit
mdr
risk
factor
appropri
antimicrobi
therapyshould
consid
patient
risk
factor
extendedspectrum
betalactamaseproduc
esbl
enterobacteriacea
legionella
anaerob
esbl
enterobactereiacea
suspect
carbapenem
use
concern
legionella
prompt
use
macrolid
fluoroquinolon
aminoglycosid
provid
would
treat
patient
recent
aspir
event
anaerob
use
clindamycin
inhibitor
carbapenem
patient
suspicion
vap
low
appropri
therapi
guid
patient
risk
factor
multidrugresist
organ
absenc
risk
factor
mdr
organ
atsidsa
guidelin
recommend
antibiot
therapi
target
streptococcu
pneumonia
haemophilu
influenza
methicillinsensit
staphylococcu
aureu
antibioticsensit
enter
gram
neg
ceftriaxon
fluoroquinolon
ampicillinsulbactam
patient
hcap
mdr
organ
distinguish
two
may
difficult
recent
resid
nurs
home
hospit
h
past
month
appear
increas
patient
risk
patient
ventilatorassoci
pneumonia
thedur
antimicrobi
therapi
guid
type
organ
studi
patient
use
random
control
design
differ
mortal
arm
treat
day
vs
day
although
patient
pseudomona
spp
higher
rate
recurr
subsequ
metaanalysi
demonstr
patient
lactos
nonfer
gramneg
bacilli
nearli
twofold
increas
odd
recurr
shorter
therapi
cours
absenc
identif
lactos
nonfer
gramneg
bacilli
ie
pseudomona
stenotrophomona
acinetobact
durat
day
use
critic
deescalateantimicrobi
therapi
specif
pathogen
identifi
cultur
neg
h
help
prevent
overus
antibiot
develop
resist
observ
data
provid
strong
safeti
signal
studi
surgic
patient
neither
mortal
vs
recurr
pneumonia
vs
differ
patient
vap
underw
deescal
vs
among
patient
vap
studi
kollef
colleagu
deescal
therapi
occur
patient
patient
lower
mortal
rate
patient
underw
escal
chang
regimen
serum
biomark
particularli
creactiv
protein
procalcitonin
pct
examin
guid
initi
discontinu
antibiot
data
inconsist
regard
clinic
util
biomark
procalcitonin
level
may
help
inform
decis
deescal
antibiot
therapi
subgroup
analys
prorata
trial
investig
found
patient
ventilatorassoci
pneumonia
assign
studi
arm
antibiot
discontinu
pct
level
reach
fewer
day
ci
day
antibiot
patient
assign
control
arm
without
differ
mortal
contrast
multicent
random
control
trial
patient
care
initi
emerg
depart
pneumonia
differ
durat
antibiot
use
treatment
decis
guid
pct
although
half
patient
hospit
popul
studi
look
procalcitonin
guid
therapi
undifferenti
septic
shock
broader
set
replic
mortal
appear
affect
procalcitonin
use
guid
therapi
although
find
durat
antibiot
heterogen
fever
pneumonia
even
icu
patient
radiograph
infiltr
patient
improv
h
respiratori
cultur
taken
antibiot
neg
vigil
othercaus
fever
central
line
infect
intraabdomin
process
etc
forcompl
pneumonia
abscess
empyema
scenario
also
prompt
reconsider
potenti
presenc
resist
pathogen
may
warrant
consult
infecti
diseas
specialist
patient
suspect
vap
obtain
endotrach
aspir
cultur
minimum
whether
pursu
bronchoscop
sampl
invas
techniqu
controversi
endotrach
aspir
neg
result
quit
help
high
neg
predict
valu
posit
result
harder
interpret
one
studi
episod
pneumonia
endotrach
aspir
found
sensit
specif
compar
protect
brush
specimen
studi
employ
clinic
pulmonari
infect
score
cpi
cutoff
noninvas
method
identifi
patient
vap
use
autopsi
find
pneumonia
gold
standard
tabl
fabrega
et
al
found
score
greater
sensit
specif
convers
bronchoscop
sampl
may
less
sensit
specif
pneumonia
random
control
trial
mix
rct
patient
found
benefit
invas
sampl
unadjust
analys
adjust
baselin
factor
recent
rct
patient
found
benefit
bronchoalveolar
lavag
endotrach
aspir
practic
perform
immedi
endotrach
aspir
patient
suspect
vap
reserv
bronchoalveolar
lavag
protect
brush
select
case
consist
idsaat
guidelin
contrast
european
respiratori
societi
guidelin
current
recommend
atsidsa
coverag
either
mgkg
vancomycin
everi
h
target
serum
trough
mgkg
mg
linezolid
everi
h
one
prospect
trial
patient
suggest
linezolid
may
superior
vancomycin
studi
patient
treat
vancomycin
cultur
persist
posit
formrsa
patient
treat
linezolid
day
howev
differ
mortal
rate
although
nephrotox
occur
greater
rate
vancomycin
research
space
continu
evolv
linezolid
may
particularli
good
option
among
patient
renal
failur
coverag
second
agent
gramneg
bacilli
may
warrant
base
local
microbiolog
pattern
exampl
patient
p
aeruginosa
vap
remain
shock
highrisk
death
antibiot
suscept
known
atsidsa
guidelin
recommend
combin
therapi
rather
monotherapi
howev
worth
note
synergi
medic
demonstr
vitro
neutropen
bacterem
patient
random
control
trial
demonstr
differ
clinic
outcom
monotherapi
combin
therapi
group
observ
cohort
studi
lancet
suggest
combin
therapi
may
harm
cohort
patient
atsidsacompli
antimicrobi
therapi
higher
risk
death
day
noncompli
group
remain
controversi
whether
individu
higher
risk
death
medic
infect
misidentif
higher
risk
mdr
infect
clinic
suspicion
identif
ventilatorassoci
pneumonia
remain
high
signific
controversi
revolv
around
establish
reliabl
epidemiolog
surveil
definit
prior
januari
center
diseas
control
surveil
report
definit
includ
sever
subject
compon
includ
chang
charact
sputum
radiograph
result
sever
studi
identifi
littl
agreement
either
across
infect
control
expert
singl
institut
across
multipl
institut
definit
sought
identifi
episod
vap
either
greater
invas
strategi
score
mechan
fare
equal
poorli
respons
effort
mani
profession
societi
cdc
gener
altern
approach
creation
entiti
ventil
associ
event
vae
intend
cast
broader
net
newlydefin
condit
intend
identifi
major
iatrogen
harm
mechan
ventil
includ
limit
pneumonia
design
reliabl
sole
base
chang
made
ventil
would
indic
worsen
oxygen
period
stabil
least
day
cours
mechan
ventil
review
radiolog
remov
definit
subsequ
subcategori
harm
includ
probabl
possibl
pneumonia
base
antibiot
chang
evid
posit
qualit
quantit
cultur
tabl
sever
studi
shown
definit
lead
reliabl
identif
individu
higher
risk
inhospit
mortal
remain
unclear
breadth
true
diseas
state
captur
definit
lilli
colleagu
found
new
vaedefinit
captur
neither
pneumonia
hospitalacquir
complic
time
contrast
boudma
colleagu
found
ventilatorassoci
condit
reason
sensit
identifi
episod
vap
specif
adult
respiratori
distress
syndrom
like
captur
alongsid
vap
larger
label
vae
first
major
intervent
studi
date
design
attempt
reduc
rate
vae
demonstr
found
spontan
awaken
trial
spontan
breath
trial
effect
howev
remain
signific
area
evolv
scienc
data
suggest
rate
vap
remain
stabl
despit
effort
prevent
affect
around
ventil
patient
modifi
risk
factorsfor
patient
vap
consid
effort
minim
likelihood
develop
vap
outset
describ
recent
updat
prevent
ventil
associ
pneumonia
societi
healthcar
epidemiolog
america
shea
infecti
diseas
societi
america
idsa
summar
tabl
